Skip to main content

Main menu

  • Online first
    • Online first
  • Current issue
    • Current issue
  • Archive
    • Archive
  • Submit a paper
    • Online submission site
    • Information for authors
  • About the journal
    • About the journal
    • Editorial board
    • Information for authors
    • FAQs
    • Thank you to our reviewers
      • Thank you to our reviewers
    • American Federation for Medical Research
  • Help
    • Contact us
    • Feedback form
    • Reprints
    • Permissions
    • Advertising
  • BMJ Journals

User menu

  • Login

Search

  • Advanced search
  • BMJ Journals
  • Login
  • Facebook
  • Twitter
JIM

Advanced Search

  • Online first
    • Online first
  • Current issue
    • Current issue
  • Archive
    • Archive
  • Submit a paper
    • Online submission site
    • Information for authors
  • About the journal
    • About the journal
    • Editorial board
    • Information for authors
    • FAQs
    • Thank you to our reviewers
    • American Federation for Medical Research
  • Help
    • Contact us
    • Feedback form
    • Reprints
    • Permissions
    • Advertising

ID: 51: CHEMOTHERAPEUTIC POTENTIAL OF LIPOXINS IN KAPOSI'S SARCOMA AND PRIMARY EFFUSION LYMPHOMA

XM Huang, AC Hwang, N Sharma-Walia
DOI: 10.1136/jim-2016-000120.89 Published 22 March 2016
XM Huang
Department of Microbiology and Immunology, Chicago Medical School, Rosalind Franklin University of Medical Sciences, North Chicago, Illinois, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AC Hwang
Department of Microbiology and Immunology, Chicago Medical School, Rosalind Franklin University of Medical Sciences, North Chicago, Illinois, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N Sharma-Walia
Department of Microbiology and Immunology, Chicago Medical School, Rosalind Franklin University of Medical Sciences, North Chicago, Illinois, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

Abstract

Current treatments for Kaposi's Sarcoma (KS) and Primary Effusion Lymphoma (PEL) rely on systemic chemotherapeutics developed for non-virus-associated cancers that target DNA replication of all dividing cells. Other treatment methods aim at keeping immune system healthy and infection under control through surgery. All of the above approaches have low efficacy, high cost, and high risk of secondary malignancies especially in immuno-compromised patients. Hence, there is an emerging need to look for alternative treatment focused on KS or PEL host molecules, such as Lipoxins. Lipoxins are anti-inflammatory molecules that can target a variety of pro-inflammatory pathways of KS and PEL. Previous results from our lab have shown that level of ALX receptor (ALXR) does not change after Kaposi's Sarcoma Herpes Virus (KSHV) infection, leading to the potential use of Lipoxins to trigger anti-inflammatory and pro-apoptotic pathways as treatment of KS and PEL.

In this study, we investigated downstream signaling in KSHV harboring body cavity B cell lymphoma (BCBL-1) cells induced by Lipoxin treatment to assess its pro-apoptotic effect. We treated 5–10×106 BCBL-1 cells with solvent control (EtOH), Lipoxin (100 mM), or Epilipoxin (100 mM) for 48 and 72 hrs. Downstream phosphorylation of Akt, NF-kB p65, and ERK were assessed using Western blotting and pro-apoptotic gene changes were detected using Real-Time PCR. Cell survival and cell cycle progression was assessed using BrdU FACS analysis. We found that Lipoxin and Epilipoxin treatment downregulated NF-kB and ERK activation via ALXR binding while Akt signaling was not affected. We also found that Lipoxin successfully upregulated pro-apoptotic genes such as BIM-1, BAX, BCL-10, and p53 compared to control. Lipoxin treatment also led to decreased S-phase progression and induction of apoptosis. In conclusion, our study suggests that Lipoxins have therapeutic potential for PEL and should be explored in KS and other PEL cell types.

Log in using your username and password

Forgot your user name or password?

Log in through your institution

You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.

PURCHASE SHORT TERM ACCESS

Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$37.00

Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.

Next
Back to top
Vol 64 Issue 4 Table of Contents
Journal of Investigative Medicine: 64 (4)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Front Matter (PDF)
Email

Thank you for your interest in spreading the word on JIM.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
ID: 51: CHEMOTHERAPEUTIC POTENTIAL OF LIPOXINS IN KAPOSI'S SARCOMA AND PRIMARY EFFUSION LYMPHOMA
(Your Name) has sent you a message from JIM
(Your Name) thought you would like to see the JIM web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
ID: 51: CHEMOTHERAPEUTIC POTENTIAL OF LIPOXINS IN KAPOSI'S SARCOMA AND PRIMARY EFFUSION LYMPHOMA
XM Huang, AC Hwang, N Sharma-Walia
Journal of Investigative Medicine Apr 2016, 64 (4) 954-955; DOI: 10.1136/jim-2016-000120.89

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Cite This
  • APA
  • Chicago
  • Endnote
  • MLA
Loading
ID: 51: CHEMOTHERAPEUTIC POTENTIAL OF LIPOXINS IN KAPOSI'S SARCOMA AND PRIMARY EFFUSION LYMPHOMA
XM Huang, AC Hwang, N Sharma-Walia
Journal of Investigative Medicine Apr 2016, 64 (4) 954-955; DOI: 10.1136/jim-2016-000120.89
Download PDF

Share
ID: 51: CHEMOTHERAPEUTIC POTENTIAL OF LIPOXINS IN KAPOSI'S SARCOMA AND PRIMARY EFFUSION LYMPHOMA
XM Huang, AC Hwang, N Sharma-Walia
Journal of Investigative Medicine Apr 2016, 64 (4) 954-955; DOI: 10.1136/jim-2016-000120.89
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Respond to this article
  • Tweet Widget
  • Facebook Like
  • Google Plus One
  • Article
  • eLetters
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

Midwestern American Federation for Medical Research Abstracts

  • ID: 33: ACUTE PANCREATITIS WITH NORMAL LIPASE AND AMYLASE ENZYMES
  • ID: 66: HENOCH-SCHONLEIN PURPURA (HSP) PRESENTING AS A LARGE PERICARDIAL EFFUSION IN AN ADULT
  • ID: 38: PRIMARY SQUAMOS CELL CARCINOMA OF THE RECTUM
Show more Midwestern American Federation for Medical Research Abstracts

Infectious Disease

  • Survival outcomes of primary cutaneous T-cell lymphoma in HIV-infected patients: a national population-based study
  • ID: 54: CUTANEOUS MUCORMYCOSIS IN A PATIENT WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A PHARMACOLOGICAL DILEMMA
  • ID: 102: WITHDRAWN
Show more Infectious Disease

Similar Articles

 

CONTENT

  • Latest content
  • Current issue
  • Archive
  • Sign up for email alerts
  • RSS

JOURNAL

  • About the journal
  • Editorial board
  • Subscribe
  • Thank you to our reviewers
  • American Federation for Medical Research

AUTHORS

  • Information for authors
  • Submit a paper
  • Track your article
  • Open Access at BMJ

HELP

  • Contact us
  • Reprints
  • Permissions
  • Advertising
  • Feedback form

© 2022 American Federation for Medical Research